← All Septerna, INC filings

Septerna, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
SEPN
Septerna, INC
10-K: Septerna's 10-K Filing Reveals Setback in Hypoparathyroidism Drug Development, Shifts Focus to Next-Generation Candidate
Septerna's 10-K filing details a strategic shift in their hypoparathyroidism program following adverse events in a Phase 1 trial, alongside updates on their broader GPCR-targeted drug development pipeline.